



Amendments to the Claims:

Claims 1-57 (Cancelled)

Claim 58 (Currently Amended): The compound of claim 75, or a pharmaceutically acceptable salt thereof, said compound having the formula:




wherein R₁ is a cycloalkyl group of the formula, n being 1-2



and R₁ can also optionally be substituted with at least one halo atom or at least one C₁ to C₃ alkyl group; R₂, R₃, R₆, R₇, R₈, R₉, or R₁₁ are each independently H, OCH₃, CH₃ or CH₂CH₃; R₄ is CN, CO₂H, CHO, CH₃, CONH₂, CHNH; R₅, R₁₀ are OH; ~~or analogues differing from the corresponding "natural" compound in the oxidation state of one or more of the ketide units,~~ with the proviso that said compounds are not borrelidin ~~(1)~~, 12-desnitrile-12-carboxyl borrelidin ~~(2)~~, 10-desmethyl borrelidin ~~(3)~~, 11-epiborrelidin ~~(4)~~ or C14,C15-*cis* borrelidin ~~analogue (5) as shown in Figure 1.~~

Claim 59 (Currently Amended): The compound of claim 75, or a pharmaceutically acceptable salt thereof, said compound having the formula:

Formula 2



wherein R_2 , R_3 , R_6 , R_7 , R_8 , R_9 , or R_{11} are each independently H, OCH_3 , CH_3 or CH_2CH_3 ; R_4 is CN, CO_2H , CHO, CH_3 , $CONH_2$, $CHNH_2$; R_5 , R_{10} are OH; ~~or analogues differing from the corresponding natural compound in the oxidation state of one or more of the ketide units (i.e. selection of alternatives from the group: CO , $CH(OH)$, CH , and CH_2)~~, and R_{12} and R_{13} are independently H or a C1-C4 alkyl group which may be optionally substituted with OH, F, Cl, SH , with the proviso that R_{12} and R_{13} are not simultaneously H.

Claim 60 (Previously Presented): The compound or salt according to claim 75, wherein R_7 , R_8 and R_9 of formulas 1 and 2 are all CH_3 .

Claim 61 (Previously Presented): The compound or salt according to claim 75, wherein R_4 of formulas 1 and 2 is CH_3 or $COOH$.

Claim 62 (Previously Presented): The compound or salt according to claim 60 wherein R_4 of formulas 1 and 2 is CH_3 or $COOH$.

Claim 63 (Previously Presented): The compound or salt according to claim 75, wherein R_4 of formulas 1 and 2 is CN.

Claim 64 (Previously Presented): The compound or salt according to claim 60 wherein R_4 of formulas 1 and 2 is CN.

Claim 65 (Previously Presented): The compound or salt according to claim 58 wherein R₁ is cyclobutane-1'-carboxylate.

Claim 66 (Previously Presented): The compound or salt according to claim 60, wherein R₁ of formula 1 is cyclobutane-1'-carboxylate.

Claim 67 (Previously Presented): The compound or salt according to claim 66, wherein R₄ of formulas 1 and 2 is CH₃ or COOH.

Claim 68 (Previously Presented): The compound or salt according to claim 58, wherein R₆, R₇, R₈ and R₉ are all CH₃, R₂ and R₁₁ are H, R₅ and R₁₀ are OH, R₄ is either CH₃, COOH or CN and R₁ is cyclopentane-1'-carboxylate or cyclobutane-1'-carboxylate.

Claim 69 (Previously Presented): The compound or salt according to claim 59, wherein R₁₂ and R₁₃ are independently CH₃ or H.

Claim 70 (Previously Presented): The compound or salt according to claim 60, wherein R₁₂ and R₁₃ of formula 2 are independently CH₃ or H.

Claim 71 (Previously Presented): The compound or salt according to claim 70, wherein R₄ of formulas 1 and 2 is CH₃ or COOH.


Claim 72 (Previously Presented): The compound or salt according to claim 59 wherein R₆, R₇, R₈ and R₉ are all CH₃, R₂ and R₁₁ are H, R₅ and R₁₀ are OH, R₄ is either CH₃, COOH or CN and R₁₂ and R₁₃ are independently CH₃ or H.

Claim 73 (Previously Presented): The compound or salt

according to claim 59 wherein R₆, R₇, R₈ and R₉ are all CH₃, R₂ and R₁₁ are H, R₅ and R₁₀ are OH, R₄ is either CH₃, COOH or CN and R₁₂ and R₁₃ are both CH₃.


Claim 74 (Cancelled)

Claim 75 (Currently Amended): A compound, said compound being selected from the group consisting of formula 1,




,and pharmaceutically acceptable salts thereof, wherein

R₁ is a cycloalkyl group of the formula, n being 1- 2,



and R₁ can also optionally be substituted with at least one halo atoms or at least one C₁ to C₃ alkyl groups; R₂, R₃, R₆, R₇, R₈, R₉, or R₁₁ are each independently H, OCH₃, CH₃ or CH₂CH₃; R₄ is CN, CO₂H, CHO, CH₃, CONH₂, CHNH; R₅, R₁₀ are OH; ~~or analogues differing from the corresponding "natural" compound in the oxidation state of one or more of the ketide units (i.e. selection of alternatives from the group: -CO-, -CH(OH)-, -CH-, and -CH₂-),~~ with the proviso that said compounds are not borrelidin ~~(1)~~, 12-desnitrile-12-carboxyl borrelidin ~~(2)~~, 10-desmethyl borrelidin ~~(3)~~, 11-epiborrelidin ~~(4)~~ or C14,C15-cis borrelidin analogue ~~(5)~~ as shown in Figure



1; and formula 2

R_2 , R_3 , R_6 , R_7 , R_8 , R_9 , or R_{11} are each independently H, OCH_3 , CH_3 or CH_2CH_3 ; R_4 is CN, CO_2H , CHO, CH_3 , $CONH_2$, $CHNH_2$; R_5 , R_{10} are OH; ~~or analogues differing from the corresponding natural compound in the oxidation state of one or more of the ketide units,~~ and R_{12} and R_{13} are independently H or a C1-C4 alkyl group which may be optionally substituted with OH, F, Cl, SH, with the proviso that R_{12} and R_{13} are not simultaneously H.

Claims 76-95 (Cancelled)